SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL. in food and drug stores combined for the 12 months ended June 30, according to Information Resources' subsidiary Towne-Oller. Sales for the antacid leader through June were up 15% compared to a year ago, the data show. Tums held a 17.7% share of the broad antacid market tracked by Towne-Oller, which includes products with additional indications outside the antacid area such as Procter & Gamble's Pepto-Bismol and McNeil's Lactaid for lactose intolerance.